Cargando…
The impact of smoking on immunological response to SARS-COV 2: a nationwide seroepidemiological study: Serine Sahakyan
BACKGROUND: Smoking influences cellular and humoral immune responses and affects the immune system by increasing inflammation and decreasing activity against infections. The current study investigates the association between smoking and immunological response to SARS-CoV-2 in the Armenian population...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594155/ http://dx.doi.org/10.1093/eurpub/ckac131.143 |
_version_ | 1784815343851536384 |
---|---|
author | Sahakyan, S Musheghyan, L Muradyan, D Sargsyan, Z Petrosyan, V Khachadourian, V Harutyunyan, A |
author_facet | Sahakyan, S Musheghyan, L Muradyan, D Sargsyan, Z Petrosyan, V Khachadourian, V Harutyunyan, A |
author_sort | Sahakyan, S |
collection | PubMed |
description | BACKGROUND: Smoking influences cellular and humoral immune responses and affects the immune system by increasing inflammation and decreasing activity against infections. The current study investigates the association between smoking and immunological response to SARS-CoV-2 in the Armenian population. METHODS: We performed a nationwide cross-sectional seroepidemiological study among the adult population (≥18 years old) in Armenia. We used a multi-stage cluster random sampling to recruit participants from the capital city and all regions of Armenia. We invited selected participants to primary healthcare facilities to provide blood samples for antibody testing followed by a phone survey on demographic characteristics, smoking status, and other variables. Logistic regression analysis was used to test the relationship between smoking and having SARS-CoV-2 antibodies adjusted for other covariates. RESULTS: 3483 people participated in the study (71% women). The total sample included 16.8% current smokers (n = 571), 8.6% past smokers (n = 294) and 76.4% never smokers (n = 2538). The prevalence of SARS CoV-2 antibodies among current smokers was statistically significantly lower as compared with never smokers (46.9% vs 73.4%, p-value<0.001). In the multivariable logistic regression model, the odds of having SARS CoV-2 antibodies among the current smokers was 70% lower (OR 0.30, 95%CI: 0.22; 0.40) compared to never smokers, when adjusted for demographic factors and the time of PCR diagnosis of COVID-19. No statistically significant difference was found between past smokers and having SARS CoV-2 antibodies. CONCLUSIONS: In addition to being a risk factor for various chronic diseases, smoking weakens immune response to infectious diseases, including COVID-19, worsening the outcomes. The significantly lower level of antibody prevalence among smokers with previous PCR confirmed COVID 19 implies a poorer immune response to the infection and not a lower risk of getting the infection. KEY MESSAGES: • Smoking weakens immune response and contributes to a higher burden of infectious diseases, such as COVID-19. • Lower level of antibody prevalence among smokers indicates a poorer immune response to the infection rather than a lower risk of getting the infection. |
format | Online Article Text |
id | pubmed-9594155 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-95941552022-11-04 The impact of smoking on immunological response to SARS-COV 2: a nationwide seroepidemiological study: Serine Sahakyan Sahakyan, S Musheghyan, L Muradyan, D Sargsyan, Z Petrosyan, V Khachadourian, V Harutyunyan, A Eur J Public Health Poster Displays BACKGROUND: Smoking influences cellular and humoral immune responses and affects the immune system by increasing inflammation and decreasing activity against infections. The current study investigates the association between smoking and immunological response to SARS-CoV-2 in the Armenian population. METHODS: We performed a nationwide cross-sectional seroepidemiological study among the adult population (≥18 years old) in Armenia. We used a multi-stage cluster random sampling to recruit participants from the capital city and all regions of Armenia. We invited selected participants to primary healthcare facilities to provide blood samples for antibody testing followed by a phone survey on demographic characteristics, smoking status, and other variables. Logistic regression analysis was used to test the relationship between smoking and having SARS-CoV-2 antibodies adjusted for other covariates. RESULTS: 3483 people participated in the study (71% women). The total sample included 16.8% current smokers (n = 571), 8.6% past smokers (n = 294) and 76.4% never smokers (n = 2538). The prevalence of SARS CoV-2 antibodies among current smokers was statistically significantly lower as compared with never smokers (46.9% vs 73.4%, p-value<0.001). In the multivariable logistic regression model, the odds of having SARS CoV-2 antibodies among the current smokers was 70% lower (OR 0.30, 95%CI: 0.22; 0.40) compared to never smokers, when adjusted for demographic factors and the time of PCR diagnosis of COVID-19. No statistically significant difference was found between past smokers and having SARS CoV-2 antibodies. CONCLUSIONS: In addition to being a risk factor for various chronic diseases, smoking weakens immune response to infectious diseases, including COVID-19, worsening the outcomes. The significantly lower level of antibody prevalence among smokers with previous PCR confirmed COVID 19 implies a poorer immune response to the infection and not a lower risk of getting the infection. KEY MESSAGES: • Smoking weakens immune response and contributes to a higher burden of infectious diseases, such as COVID-19. • Lower level of antibody prevalence among smokers indicates a poorer immune response to the infection rather than a lower risk of getting the infection. Oxford University Press 2022-10-25 /pmc/articles/PMC9594155/ http://dx.doi.org/10.1093/eurpub/ckac131.143 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the European Public Health Association. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Poster Displays Sahakyan, S Musheghyan, L Muradyan, D Sargsyan, Z Petrosyan, V Khachadourian, V Harutyunyan, A The impact of smoking on immunological response to SARS-COV 2: a nationwide seroepidemiological study: Serine Sahakyan |
title | The impact of smoking on immunological response to SARS-COV 2: a nationwide seroepidemiological study: Serine Sahakyan |
title_full | The impact of smoking on immunological response to SARS-COV 2: a nationwide seroepidemiological study: Serine Sahakyan |
title_fullStr | The impact of smoking on immunological response to SARS-COV 2: a nationwide seroepidemiological study: Serine Sahakyan |
title_full_unstemmed | The impact of smoking on immunological response to SARS-COV 2: a nationwide seroepidemiological study: Serine Sahakyan |
title_short | The impact of smoking on immunological response to SARS-COV 2: a nationwide seroepidemiological study: Serine Sahakyan |
title_sort | impact of smoking on immunological response to sars-cov 2: a nationwide seroepidemiological study: serine sahakyan |
topic | Poster Displays |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594155/ http://dx.doi.org/10.1093/eurpub/ckac131.143 |
work_keys_str_mv | AT sahakyans theimpactofsmokingonimmunologicalresponsetosarscov2anationwideseroepidemiologicalstudyserinesahakyan AT musheghyanl theimpactofsmokingonimmunologicalresponsetosarscov2anationwideseroepidemiologicalstudyserinesahakyan AT muradyand theimpactofsmokingonimmunologicalresponsetosarscov2anationwideseroepidemiologicalstudyserinesahakyan AT sargsyanz theimpactofsmokingonimmunologicalresponsetosarscov2anationwideseroepidemiologicalstudyserinesahakyan AT petrosyanv theimpactofsmokingonimmunologicalresponsetosarscov2anationwideseroepidemiologicalstudyserinesahakyan AT khachadourianv theimpactofsmokingonimmunologicalresponsetosarscov2anationwideseroepidemiologicalstudyserinesahakyan AT harutyunyana theimpactofsmokingonimmunologicalresponsetosarscov2anationwideseroepidemiologicalstudyserinesahakyan AT sahakyans impactofsmokingonimmunologicalresponsetosarscov2anationwideseroepidemiologicalstudyserinesahakyan AT musheghyanl impactofsmokingonimmunologicalresponsetosarscov2anationwideseroepidemiologicalstudyserinesahakyan AT muradyand impactofsmokingonimmunologicalresponsetosarscov2anationwideseroepidemiologicalstudyserinesahakyan AT sargsyanz impactofsmokingonimmunologicalresponsetosarscov2anationwideseroepidemiologicalstudyserinesahakyan AT petrosyanv impactofsmokingonimmunologicalresponsetosarscov2anationwideseroepidemiologicalstudyserinesahakyan AT khachadourianv impactofsmokingonimmunologicalresponsetosarscov2anationwideseroepidemiologicalstudyserinesahakyan AT harutyunyana impactofsmokingonimmunologicalresponsetosarscov2anationwideseroepidemiologicalstudyserinesahakyan |